Tvardi Therapeutics, Inc. (TVRD)

Tvardi Therapeutics, Inc. (TVRD) is a healthcare company (biotechnology) based in the United States. The share price is $1.01, down 8.18% on the day, which values the company at $13.5M. Price as of 17 Nov 2026, 21:03 UTC, from Yahoo Finance.

Key facts

Share price
$1.01−8.18% today
Market value
$13.5M
200-week average
$43.5798% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Tvardi Therapeutics, Inc. in more detail

TVRD trades at -0.6× next year's expected earnings. It sits 98% below its 200-week average of $43.57.

In its favour: More cash than debt. Worth checking: Weak Piotroski score.

1 of the superinvestors tracked here hold TVRD, including David Greenspan (0.0% of the portfolio).

Superinvestors holding TVRD

1 of the investors tracked here report a position in their latest 13F filing.

Tvardi Therapeutics, Inc. (TVRD): questions and answers

What is Tvardi Therapeutics, Inc.'s market cap?

Tvardi Therapeutics, Inc. is valued at $13.5M at a share price of $1.01.

Is TVRD above its 200-week moving average?

No. TVRD is 97.7% below its 200-week average of $43.57. Long-term investors watch that line because strong companies rarely trade below it for long.

Does TVRD pay a dividend?

Tvardi Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own TVRD?

In their latest quarterly filings, David Greenspan (0.0% of the portfolio) hold TVRD. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Tvardi Therapeutics, Inc. (TVRD) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TVRD

Underlying data: Yahoo Finance; company filings with the SEC.